Home/Filings/4/0001140361-25-005535
4//SEC Filing

Kestenberg-Messina Kaitlin M. 4

Accession 0001140361-25-005535

CIK 0001368514other

Filed

Feb 20, 7:00 PM ET

Accepted

Feb 21, 9:01 PM ET

Size

9.2 KB

Accession

0001140361-25-005535

Insider Transaction Report

Form 4
Period: 2025-02-19
Kestenberg-Messina Kaitlin M.
COO and SVP, Compliance
Transactions
  • Award

    Common Stock

    2025-02-19+77,784524,016 total
  • Award

    Stock Option (right to buy)

    2025-02-19+116,279116,279 total
    Exercise: $16.07Exp: 2035-02-19Common Stock (116,279 underlying)
Footnotes (4)
  • [F1]These shares represent restricted stock units ("RSUs") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the reporting person's continued service as of the applicable vesting date.
  • [F2]Includes, as of the transaction date (i) 77,784 unvested RSUs granted on February 19, 2025 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 192,320 unvested RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iii) 22,500 unvested RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (iv) 71,250 unvested RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date;
  • [F3](continued from footnote 2) (v) 20,000 unvested RSUs granted on March 7, 2022, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; (vi) 5,000 unvested RSUs granted on February 25, 2021, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the reporting person's continued service as of the applicable vesting date; and (vii) 135,162 shares of common stock owned by the reporting person, which reflects the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
  • [F4]The options vest over four years with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 19, 2029 in accordance with the Plan.

Issuer

ADMA BIOLOGICS, INC.

CIK 0001368514

Entity typeother

Related Parties

1
  • filerCIK 0002017423

Filing Metadata

Form type
4
Filed
Feb 20, 7:00 PM ET
Accepted
Feb 21, 9:01 PM ET
Size
9.2 KB